Completed
OBSERVATIONAL
NCT04067999
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.
Interventions
Name:
Semaglutide
Type:
DRUG
Description:
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Primary Outcomes
Measure:
Change in Glycated Haemoglobin A1c (HbA1c) (measured in percent)
TimeFrame:
Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Description:
Measured in % points
Measure:
Change in Glycated Haemoglobin A1c (HbA1c) (measured in mmol/mol)
TimeFrame:
Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Description:
Measured in mmol/mol
Trial Information
NCT ID
NCT04067999
Status
Completed
Study Type
OBSERVATIONAL
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025